14040 Danielson Street
234 articles with ResMed Inc.
ResMed announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software.
ResMed Acquires HB Healthcare to Help Millions of Koreans Living with Sleep Apnea, Other Respiratory Conditions
ResMed, a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, announced that is has completed the acquisition of HB Healthcare to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions.
Settlement will end infringement cases worldwide
- AirFit N30i adds a top-of-head mask-to-tube connection to ResMed’s expanding CPAP mask portfolio, helps the wearer move and sleep in any position - New “cradle” cushion sits under the nose, designed to reduce facial markings and irritation
Mobi delivers an optimal balance of oxygen output, battery life and weight for effective therapy wherever people go
Safeguard to realize $41.4 million in cash proceeds, representing an approximate 3x cash-on-cash return and 34% IRR
ResMed is now poised to provide a broader suite of solutions for COPD treatment
Safeguard Scientifics, Inc.. (NYSE:SFE) (Safeguard or the Company) today announced that its partner company, Propeller Health, signed a definitive agreement to be acquired by ResMed (NYSE:RMD) (ASX:RMD) for $225 million in cash.
ResMed to Acquire Propeller Health, a Leader in COPD and Asthma Connected Health Solutions, for $225 Million
Establishes ResMed as a leader in COPD patient management, across all stages of the disease
Gill’s 25 years of health and consumer tech experience across Asia, Europe and the Middle East will help guide ResMed’s expanding global connected health businesses
Establishes ResMed as a leader in out-of-hospital software-as-a-service offerings
Strong year-over-year growth in revenue, net income, and earnings per share
Court finds headgear used on Simplus and Eson 2 CPAP masks infringes ResMed patent
Nearly 2 to 1 patients prefer AirFit F30 over the current minimal-contact full face market leader
ResMed (NYSE: RMD, ASX: RMD) today announced it will report its first quarter of fiscal year 2019 results on Thursday, October 25, 2018, after the New York Stock Exchange market closes.
AirFit F30 outperforms leading mask of its kind in fit, seal, ease of use.
ResMed files new infringement action against Fisher & Paykel’s Simplus, Eson and Eson 2 masks in the International Trade Commission to stop their importation to and sale in the United States
Other upgrades include easy interface switching and program naming to improve ease of use
Revenue increased 12% to $623.6 million; up 10% on a constant currency basis
Verily will team up with San Diego-based ResMed, a company that specializes in the treatment of sleep disorders, to launch a new joint business venture to address sleep apnea and other sleeping disorders.